Status:
UNKNOWN
Phase II Study of Six Hours Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma
Lead Sponsor:
Instituto Nacional de Cancerologia de Mexico
Collaborating Sponsors:
National Council of Science and Technology, Mexico
Conditions:
Advanced Malignant Pleural Mesothelioma
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Malignant pleural mesothelioma (MPM) is a rare disease, but with a very high mortality. MPM is frequently found in advanced stages. The standard treatment in advanced pleural mesothelioma is cisplatin...
Detailed Description
Malignant pleural mesothelioma is a rare disease, but with a high mortality. It usually develops in people who were exposed to asbestos, with a latency period ranging from 20 to 40 years. Most of thes...
Eligibility Criteria
Inclusion
- Histologic Diagnosis of Pleural Mesothelioma
- Multidisciplinary assessment and considered not candidate for resection.
- Karnofsky \> = 70 or ECOG \< 2
- Adequate Hematologic, renal and hepatic function.
Exclusion
- Superior vena cava syndrome, severe bone pain or CNS metastasis
- Not candidate for chemotherapy (Poor functional status: ECOG \> 2)
- The patient refuses to participate
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT01869023
Start Date
November 1 2010
End Date
December 1 2017
Last Update
March 3 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Nacional de Cancerología
Mexico City, Mexico